Introducing NEJM Evidence Launching January 2022, NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making. The volume of clinical research continues to grow, yet the standards to establish and validate claims, especially as related to clinical practice, have not followed…
Understand the real reasons reproducibility reform fails Lack of rigour is often blamed on pressure to publish. But ethnographers can find out what truly keeps science from upping its game. Nicole C. Nelson A decade ago, the US National Institute of Neurological Disorders and Stroke convened a workshop on how to improve the rigour of…
Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19 Husam M. Salah, et al. Repurposing of existing medications has widely been used in studies since the emergence of coronavirus disease 2019 (COVID-19). Besides dexamethasone in selected patients, no medical treatment to date has been shown to improve mortality in patients with COVID-19 infection. Aspirin…
Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration Thomas F. Osborne et al. Abstract There is growing evidence that thrombotic and inflammatory pathways contribute to the severity of COVID-19. Common medications such as aspirin, that mitigate these pathways, may decrease COVID-19 mortality. This retrospective assessment was designed to quantify…
Global Incidence of Acute Pancreatitis Is Increasing Over Time: A Systematic Review and Meta-Analysis Jordan P. Iannuzzi et al. Background & Aims Acute pancreatitis is a common disease with significant associated morbidity and mortality. We performed a systematic review and meta-analysis of population-based studies to explore the changing temporal trends of acute pancreatitis incidence globally.…
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients Angélica Jayk Bernal et al. BACKGROUND New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS We conducted a phase 3, double-blind,…